The Hungarian pharmaceutical company Gedeon Richter Plc. - together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH - has announced on the website of the Budapest Stock Exchange that the European Commission has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 […]

















